Formulary Management: How to Cut Pharmacy Spend Without Creating Employee Headaches

Why “Silent Savings” Matter More Than “Big Bang” Announcements

Last spring, I watched a 950-employee manufacturer in the Midwest try to plug a $200,000 pharmacy budget gap by removing three name-brand drugs from their formulary. The CFO was proud. The PBM projected savings of $17,400 per month. By July, the HR inbox was flooded with complaints from frustrated employees whose doctors suddenly faced rejected prior authorizations, and the company pulled two of the drugs back in, erasing half the expected savings and souring the HR team on future changes.

This isn’t rare. Formulary management is one of the few levers that can deliver 8-15% pharmacy savings for mid-size employers ($120,000 to $450,000+ per year on a $3 million pharmacy spend). But if you ignore member disruption, savings evaporate, and you risk cultural damage that can last years. The best employers know the art of “silent savings.” They tweak formularies in ways that trim cost without drawing employee ire or generating extra noise for HR.

Why a High GDR Doesn’t Equal Low Costs, And Where the Hidden Spend Lives

Lots of employers over-focus on their generic dispensing rate (GDR). It's true that a GDR of 91.3% looks great on a quarterly report. But if your specialty drug trend is out of control, or your brand drug “leakage” stays high, you’re still missing the real savings opportunities.

For example, a 400-life professional services company I worked with last year had a GDR above 92%, but their specialty spend reached 55% of total pharmacy dollars. Five Humira patients accounted for $170,000 of annual spend, more than their entire generic drug spend combined. The CFO kept asking about generics, but the real action was in biosimilar adoption and enhanced specialty management.

You can pull GDR and brand utilization rates from almost any PBM report, or get deeper insights from RxPBM.ai if you want to compare against regional and industry peers. But don’t stop at a “great” GDR. Look for brand drugs with generic equivalents, high-cost specialty claims that could move to biosimilars, and categories (like GLP-1s or migraine injectables) where formulary coverage and step therapy rules can actually nudge spend downward with minimal member pushback.

Step Therapy and Exclusions: Where to Draw the Line for Real Savings Without Blowback

Step therapy and exclusions are among the most effective tools in a formulary manager’s playbook, but execution matters. The best savings happen when you target categories with true therapeutic alternatives, not when you remove single-source drugs that have passionate patient followings.

Take GLP-1s as an example. In 2023, we saw Ozempic, Wegovy, and Mounjaro (semaglutide and tirzepatide) surge in use, $1,000+ per month per patient, sometimes with shaky clinical justification. For a 700-life group with only 9 GLP-1 claims, a simple step edit requiring proof of Type 2 diabetes (not just weight loss) reduced inappropriate prescribing and saved $48,000 annually. Just as critical, a pre-rollout communication plan for employees and prescribers almost eliminated negative feedback.

On the other hand, blanket exclusions often create headaches. Removing all migraine injectables, for instance, can generate dozens of appeals, lost productivity, and physician calls. Far better to design exclusions that steer first to generics (like sumatriptan or rizatriptan) or require trial and failure of less costly agents before approving high-priced drugs like Aimovig or Ubrelvy. The right exclusions might only save $25,000 on a $1 million spend, but they come with far less HR noise than a broad-brush approach.

Consult your PBM or an expert pharmacy benefits consultant before launching any exclusion or step therapy program. Some categories, oncologics, immunologics, drugs requiring rapid titration, are high-risk for clinical fallout and member disruption. Use ClinicalRx.ai for quick evidence on therapeutic alternatives and risks in specific drug classes. And never underestimate how a few angry employee calls can sway leadership’s appetite for further change.

Tiered Formularies, Copay Tools, and Why Communication Outperforms Complexity

PBMs love multi-tier formularies, three, four, even five tiers with escalating copays or coinsurance. In theory, these drive use of preferred generics and brands. In practice, most employees only notice when their drug jumps a tier or is excluded altogether.

If you’re managing a plan with limited HR staff, simpler is often better. I’ve seen 200-employee nonprofits save $28,000 a year by moving from a two- to a three-tier plan, with only a handful of member complaints. However, when a 2,000-life technology firm added a specialty tier with $300 copays and little pre-communication, HR needed to field 45 employee concerns in the first month. You have to match the formulary structure to your workforce’s communication needs and bandwidth for disruption.

Copay assistance programs, like manufacturer copay cards, patient assistance programs (AbbVie myAbbVie Assist, Pfizer RxPathways), or discount platforms such as RxSaver.ai, can soften the blow for employees facing higher out-of-pocket costs. Many PBMs offer accumulator or maximizer programs to offset plan costs, but these can create employee confusion if not handled carefully. Roll out these programs with clear, jargon-free employee communications and a simple FAQ. If you lack internal bandwidth for this, your PBM or benefits consultant should provide one.

Finally, remember that communication is more important than formulary complexity. Most member complaints don’t come from changes themselves, but from surprises. Give employees 30 to 60 days’ warning, explain why changes are being made, and offer a dedicated support line for affected members. This can cut HR ticket volume by half and preserve goodwill.

Realistic Savings Scenarios, And Knowing When to Leave Well Enough Alone

For most mid-market groups, a targeted formulary intervention can save 8-15%, but every category and company is different. Let’s say you manage pharmacy for a 600-employee hospital system with a $2.1 million annual pharmacy spend ($125 PMPM). Tightening GLP-1 prior authorization saves $35,000. Moving five Humira patients to biosimilars like Hadlima or Cyltezo trims $85,000. Adding a third formulary tier nets another $27,000. That’s nearly $150,000 in annual savings, achieved with fewer than 15 employee complaints, and most resolved with a single phone call.

But not every change pays off. Some exclusions or step therapies generate more headaches than they’re worth, especially with rare-disease drugs or complex pediatric therapies. Sometimes, a 2% savings opportunity just isn’t worth the HR disruption or physician pushback. A pharmacy benefits consultant can help quantify the dollars, but only you know your company’s appetite for employee complaints. Sometimes, the best strategy is to sit tight and wait for new biosimilars or generics to launch (track these via RxNews.ai).

Formulary management works best as an ongoing conversation, not a one-time overhaul. Review your formulary annually, tap your PBM or consultant for benchmark data, and ask your HR team which changes actually generated noise (and which were headaches in name only). Over time, you’ll build a benefits program that saves real money without putting your HR team in the firing line.